Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system

Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system

Background: The buprenorphine transdermal system (BTDS) is approved in the US for the management of chronic pain. Due to its high affinity for mu-opioid receptors with a slow dissociation profile, buprenorphine may potentially displace or prevent the binding of competing mu-opioid-receptor agonists,...

Full description

Bibliographic Details
Main Authors: Silverman, Sanford, Raffa, Robert B, Cataldo, Marc, Kwarcinski, Monica, Ripa, Steven R.
Other Authors: Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol
Language:en
Published: DOVE MEDICAL PRESS LTD 2017
Subjects:
buprenorphine transdermal system
ER opioids
chronic low-back pain
chronic noncancer pain
Butrans
supplemental analgesia
breakthrough pain
Online Access:http://hdl.handle.net/10150/624646
http://arizona.openrepository.com/arizona/handle/10150/624646

Internet

http://hdl.handle.net/10150/624646
http://arizona.openrepository.com/arizona/handle/10150/624646

Similar Items